Preliminary study correlating CX3CL1/CX3CR1 expression with gastric carcinoma and gastric carcinoma perineural invasion

AIM:To study the relationship between the CX3CL1chemokine,its receptor CX3CR1,and gastric carcinoma/gastric carcinoma perineural invasion(PNI).METHODS:Thirty cases of gastric carcinoma were surgically resected(radical resection or palliative resection)between February 2012 and July 2012.Tumour and tumour-adjacent tissues were evaluated for the presence of CX3CL1(ELISA)and CX3CR1(immunohistochemistry and Western blotting)in an effort to analyse the relationship between CX3CL1/CX3CR1 and gastric carcinoma/gastric carcinoma PNI.RESULTS:Of these 30 cases,14 were PNI-positive(46.7%).No significant differences in CX3CL and CX3CR1 expression in tumour-adjacent tissues were found between the PNI positive and negative groups.Expression levels of CX3CL and CX3CR1 in tumour tissues were significantly higher than those in adjacent tissues(P<0.01),and were significantly higher in tumour tissues from the PNI-positive group compared to the PNI-negative group(P<0.01).CONCLUSION:CX3CL1/CX3CR1 expression may be associated with the occurrence and development of gastric carcinoma as well as gastric carcinoma PNI.     

CX3CL1/CX3CR1轴在HIV感染者动脉粥样硬化性心脏病中的作用北大核心CSCD

动脉粥样硬化性心脏病目前是HIV/AIDS患者死亡的主要原因之一,也是HIV/AIDS患者慢病管理的重要一环。然而,HIV/AIDS患者动脉粥样硬化性心脏病的发生机制仍不完全清楚。研究表明,慢性持续性炎症是HIV/AIDS患者心血管疾病发生的主要诱因。CX3CL1/CX3CR1是重要的炎症性趋化因子,HIV/AIDS患者中CX3CL1/CX3CR1的表达上调,可通过细胞趋化作用、炎性反应等参与动脉粥样硬化(AS)的形成。因此,了解CX3CL1/CX3CR1在HIV/AIDS患者动脉粥样硬化过程中的作用机制有助于研发新的干预措施,延缓甚至预防HIV/AIDS患者动脉粥样硬化性心脏病的发生发展。本文将从CX3CL1/CX3CR1与动脉粥样硬化的关系,CX3CL1/CX3CR1在HIV/AIDS患者动脉粥样硬化性心脏病中的作用机制等方面进行综述。     

冠心病外周血中CX3CL1、CX3CR1的表达及临床意义

目的研究冠状动脉粥样硬化性心脏病(冠心病)外周血中趋化因子(CX3CL1)、细胞受体(CX3CR1)的表达及临床意义。方法选取2015年1月~2016年10月于沧州市中心医院冠心病患者195例记为观察组,其中接受冠脉造影合并经皮冠状动脉介入治疗(PCI)治疗者157例,单纯接受冠脉造影但未PCI治疗者38例。根据患者的病情分成稳定型心绞痛(SAP)组53例,不稳定型心绞痛(UAP)组56例,急性心肌梗死(AMI)组86例,其中ST段抬高型AMI(STEMI)48例、非ST段抬高型AMI(NSTEMI)38例。另选同期在医院接受健康体检的志愿者60例纳入对照组。酶联免疫ELISA法检测其外周血内CX3CL1水平,利用流式细胞术测定CD4~+CD28-CX3CR1~+T细胞受体的有关表达水平。结果观察组CX3CL1及CD4~+CD28-CX3CR1~+T水平均较对照组高(P均0.05)。UAP组及AMI组的CX3CL1及CD4~+CD28-CX3CR1~+T水平高于SAP组,且AMI组较UAP组也更高,差异均有统计学意义(P均0.05)。冠脉造影合并PCI治疗者术前和术后的外周血CX3CL1和CD4~+CD28-CX3CR1~+T水平均分别较冠脉造影但未PCI治疗者升高,且STEMI者较NSTEMI者更高,差异均有统计学意义(P均0.05)。患者外周血CX3CL1和CD4~+CD28-CX3CR1~+T呈正相关(r=0.794)。结论冠心病外周血中CX3CL1与CX3CR1的表达均明显上调,且二者之间存在正相关,临床上可对二者的表达水平进行监测,从而更加有效地服务临床诊治过程。     

趋化因子CX3C受体1基因rs3732378多态性与急性冠状动脉综合征的相关性

目的探讨趋化因子CX3C受体1(CX3CR1)基因rs3732378单核苷酸多态性与急性冠状动脉综合征(ACS)的相关性。方法连续收集中国北方汉族人群951例,其中男性520例,女性431例,年龄35~75岁。根据冠状动脉造影(CAG)结果分为2组:(1)病例组(n=512):ACS患者;(2)对照组(n=439):非冠心病患者。病例组根据CAG检查血管病变支数分为3个亚组。采用测序法测定CX3CR1基因rs3732378单核苷酸多态位点的基因型。用多因素Logistic回归分析CX3CR1基因rs3732378多态性与ACS发病风险的关系。应用酶联免疫吸附法检测血浆中趋化因子CX3C配体1(CX3CL1)表达水平。结果两组CX3CR1基因rs3732378的基因型及等位基因的分布频率无显著性差异(P0.05)。rs3732378多态位点与ACS发病风险的总体和分层分析结果表明,CX3CR1基因rs3732378多态位点的3种基因型TT、TC和CC均不能增加ACS的发病风险(P0.05)。亚组分析显示,rs3732378多态位点的基因型和等位基因与冠状动脉血管病变支数无相关性(χ2=0.135,P=0.998;χ2=0.026,P=0.987)。病例组和对照组血浆中CX3CL1表达水平在rs3732378三种基因型无差异(P0.05)。结论 CX3CR1基因rs3732378多态位点不是ACS的易感基因,rs3732378多态性没有增加中国北方汉族人群ACS的风险。     

CX3CL1/CCL26-CX3CR1通路在原发性胆汁性胆管炎免疫机制中的作用

目的探究CX3CL1/CCL26-CX3CR1通路在原发性胆汁性胆管炎(primary biliary cholangitis, PBC)免疫机制中的作用。方法收集PBC患者和健康对照者外周血及肝脏病理标本,采用ELISA检测血浆CX3CL1及CCL26水平,流式细胞术检测外周血单个核细胞各亚群中CX3CR1~+细胞比例。使用免疫组化分析肝活检组织中CX3CL1和CCL26表达情况。采用ELISA和流式细胞术检测不同细胞因子及LPS刺激下,体外培养的人肝内胆管上皮细胞中CX3CL1/CCL26-CX3CR1通路表达水平变化。结果共纳入PBC患者40例、健康对照者18例。PBC患者血浆CX3CL1水平[(0.690±0.271)ng/mL]较健康对照者[(0.540±0.101)ng/ml]显著升高(P=0.044)。PBC患者血浆CCL26浓度[(8.94±4.09)pg/mL]较健康对照者[(6.75±1.86)pg/mL]有升高趋势,但无统计学差异(P=0.104)。与健康对照者相比,PBC患者CX3CR1表达水平在NKT-like细胞[(63.5±25.4)%vs.(78.6±18.0)%,P=0.026]和CD4~+ T细胞[(5.5±5.4)%vs.(13.7±9.0)%,P=0.003]中显著增高,且后者这一差异在其CD28~+和CD28~-亚群中均显著。PBC患者肝脏胆管上皮细胞同时高表达CX3CL1和CCL26,健康对照者则弱表达CX3CL1,无CCL26表达。人肝内胆管上皮细胞CX3CL1表达水平在IFN-γ刺激下显著增加,CCL26表达在IL-4、IL-13刺激下显著增加;在IFN-γ刺激下,CX3CR1表达显著升高。结论 PBC患者肝内胆管上皮细胞可能在IFN-γ刺激下CX3CL1表达增加,在IL-4和IL-13刺激下CCL26表达增加,其受体CX3CR1在外周血NKT-like细胞和CD4~+ T细胞中表达上调。CX3CL1和CCL26可能通过CX3CR1协同介导PBC胆管上皮损伤。     

Fractalkine与肾脏疾病

随着人们预期寿命的增加和糖尿病肾病发病率的增长,肾脏疾病将给社会带来巨大挑战。Frac-talkine(CX3CL1)是目前已知惟一的CX3C-趋化因子,它既可作为趋化因子,也可作为黏附因子,CX3CR1是其特异受体。关于Fractalkine与肾脏疾病之间的研究近年来有许多进展,本文综述了这方面的一些文献。     

趋化因子CX3C配体1在原发性干燥综合征合并间质性肺疾病中的临床意义

目的探讨趋化因子CX3C配体1(CX3CL1)在pSS合并间质性肺疾病(ILD)中的临床意义。方法纳入2019年12月至2020年12月桂林医学院附属医院风湿免疫科就诊的pSS患者共103例[合并ILD 42例(pSS-ILD组), 非ILD 61例(pSS组)], 桂林医学院附属医院健康体检中心健康体检者46名(健康对照组);收集入组患者的基本资料、临床表现、临床指标、肺功能、肺高分辨率CT(HRCT)及血清标本;ELISA法检测CX3CL1、涎液化糖链抗原-6(KL-6)在3组血清中的水平, 分析CX3CL1与pSS-ILD和pSS患者的临床相关指标的相关性。采用独立样本t检验。Kruskal-WallisH检验、Pearson相关、Logistic回归分析方法进行统计学分析。结果①CX3CL1、KL-6在pSS-ILD组比pSS组、健康对照组高[CX3CL1:9.08(3.97, 30.56)ng/ml、8.12(6.16, 8.89)ng/ml与7.09(5.86, 9.07)ng/ml, H=3.53, P=0.019;KL-6:19.08(8.05, 24.72)mU/ml...     

缺血性脑血管病患者趋化因子受体CX3CR1基因V2491多态性的研究

目的 探讨缺血性脑血管病(ICVD)患者趋化因子受体CX3CR1基因V2491的多态性及其频率.方法 采用聚合酶链反应和限制性片段长度多态性方法检测ICVD患者(脑梗死、腔隙性脑梗死、短暂性脑缺血发作)及健康对照者的CX3CR1基因V2491的多态性及频率.结果 对照组CX3CR1基因V2491只有ⅤⅤ和Ⅵ基因型,ICVD组有ⅤⅤ、Ⅵ和Ⅱ3种基因型;ICVD组Ⅰ等位基因频率明显高于对照组(P<0.01);CX3CR1基因型及Ⅰ等位基因频率在不同类型ICVD患者之间无统计学差异.结论 CX3CR1基因V2491多态性可能与ICVD有关.     

单核细胞CX3C趋化因子受体1表达与冠状动脉狭窄性疾病的关系

目的探讨单核细胞CX3C趋化因子受体1(CX3CR1)表达与冠状动脉狭窄性疾病的关系。方法选择冠状动脉血管狭窄≥50%患者70例、冠状动脉血管狭窄50%患者23例与无冠状动脉病变的非冠状动脉粥样硬化性心脏病志愿者24例分别为狭窄组、不明显病变组与对照组。用流式细胞术测定单核细胞CX3CR1荧光表达强度,比较3组单核细胞CX3CR1表达水平,进行Spearman相关分析,多因素logistic回归分析,ROC曲线分析相关危险因素。结果狭窄组、不明显病变组、对照组CX3CR1荧光强度分别为4.94%(2.41%,6.58%)、2.02%(1.25%,3.57%)、1.68%(1.09%,2.24%),3组比较有统计学差异(Hc=31.025,P0.01)。与对照组比较,狭窄组CX3CR1荧光强度明显升高,有统计学差异(Z=4.934,P0.01)。TG和CX3CR1是冠状动脉狭窄性疾病发病的危险因素(P=0.048,P=0.026)。CX3CR1荧光强度在临界值为2.91%时,敏感性为64.1%,特异性为91.7%,曲线下面积为0.810,CX3CR1对冠状动脉狭窄病变有一定的诊断效力(95%CI:0.728~0.891,P0.01)。结论单核细胞CX3CR1高表达是冠状动脉狭窄性疾病发病的危险因素,对冠状动脉狭窄性疾病诊断有一定的效力。     

趋化因子Fractalkine受体CX3CR1基因多态性与动脉粥样硬化

动脉粥样硬化是一种多因素共同作用的疾病,炎症被认为是动脉粥样硬化疾病的独立危险因素,CX3C是一类独特的趋化因子,其受体CX3CR1的基因多态性与动脉粥样硬化的关系也日见报道,然而两者是否有必然联系,目前尚未知晓。本文就趋化因子受体CX3CR1的结构、生物学特性及与动脉粥样硬化之间关系做一综述。     

Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis

BACKGROUND: Fractalkine expressed on endothelial cells mediates activation and adhesion of leucocytes expressing its receptor, CX(3)CR1. Soluble fractalkine exhibits chemotactic activity for leucocytes expressing CX(3)CR1. OBJECTIVE: To determine the role of fractalkine and its receptor in systemic sclerosis (SSc) by assessing their expression levels in patients with this disease. METHODS: The expression of fractalkine and CX(3)CR1 in the skin and lung tissues was immunohistochemically examined. Circulating soluble fractalkine levels were examined by enzyme linked immunosorbent assay (ELISA). Blood samples from patients with SSc were stained for CX(3)CR1 with flow cytometric analysis. RESULTS: CX(3)CR1 levels on peripheral monocytes/macrophages and T cells were found to be raised in patients with diffuse cutaneous SSc. The numbers of cells expressing CX(3)CR1, including monocytes/macrophages, were increased in the lesional skin and lung tissues from patients with diffuse cutaneous SSc. Fractalkine was strongly expressed on endothelial cells in the affected skin and lung tissues. Soluble fractalkine levels were significantly raised in sera and were associated with raised erythrocyte sedimentation rates, digital ischaemia, and severity of pulmonary fibrosis. CONCLUSIONS: Up regulated expression of fractalkine and CX(3)CR1 cooperatively augments the recruitment of mononuclear cells expressing CX(3)CR1 into the affected tissue of SSc, leading to inflammation and vascular injury.     

CX3CR1 regulates angiogenesis and activation of pro-angiogenic factors and triggers macrophage accumulation in experimental hepatopulmonary syndrome model

ObjectivePrevalence of hepatopulmonary syndrome (HPS) ranges from 4% to 47% in patients with cirrhosis. This study aimed to explore possible relationship between CX3CR1 and angiogenesis or macrophage accumulation in pathological process of HPS.Material and methodsWide-type C57Bl/6 mice were divided into WT-sham, WT-common bile duct ligation (WT-CBDL), WT-CBDL plus antibody (WT-CBDL + Ab) and WT-CBDL plus Bevacizumab. The CX3CR1^GFP/GFP mice were grouping into CX3CR1 GFP/GFP-sham, CX3CR1 GFP/GFP-CBDL and CX3CR1 GFP/GFP-CBDL + Bevacizumab group. Intrapulmonary expression of Akt, pAkt, ERK, pERK, iNOS, VEGF, PDGF was measured using biological technology. Hematoxylin-eosin (H&E) staining and immunohistochemical analysis were used to evaluate changes of pulmonary tissues including pathological abnormality, angiogenesis and macrophage accumulation.ResultsBlockade CX3CR1 pathway inhibited angiogenesis, macrophage accumulation and pathological changes of lung tissues. Blockade of CX3CR1 pathway reduced pAkt, pERK, iNOS, PDGF and VEGF activation. CX3CR1 contributed to the process of angiogenesis and activate the pro-angiogenic factors. CX3CR1 deficiency obviously reduced the macrophage accumulation. Inhibition of VEGF by Bevacizumab improved intrapulmonary angiogenesis and pathological changes of lung tissues. Inhibition of VEGF by Bevacizumab retarded the production of pAKt, PDGF, and iNOS. Inhibition of VEGF by Bevacizumab reduced CX3CL1 production.ConclusionCX3CR1 could regulate the angiogenesis and activation of pro-angiogenic factors, including pAKT, pERK, iNOS, VEGF and PDGF in the process of hepato-pulmonary syndrome. Moreover, CX3CR1 could also contribute to the macrophage accumulation.     

The V249I polymorphism of the CX3CR1 gene is associated with fibrostenotic disease behavior in patients with Crohn's disease

OBJECTIVES: CX3CR1, the receptor of CX3CL1/fractalkine, is involved in regulation of inflammatory response and the CX3CR1-I249-M280 naturally occurring mutants are associated with altered binding to the ligand. Our aim was to evaluate the frequency of CX3CR1 V249I and T280M polymorphisms and NOD2/CARD15 mutations in Crohn's disease patients and to search for a relationship with phenotype. METHODS: Clinical data were retrospectively collected. V249I and T280M polymorphisms of CX3CR1 gene and NOD2/CARD15 mutations (R702W, G908R, 3020InsC) were identified. RESULTS: Two hundred and thirty-nine patients (140 females, 39.7+/-14.1 years) were included. About 37.4% were heterozygous and 8.8% were homozygous for the V249I CX3CR1 polymorphism, 18.1% were heterozygous and 1.3% homozygous for the T280M CX3CR1 polymorphism and 35.9% had at least one of the three mutations of NOD2/CARD15. The T280M CX3CR1 polymorphism was not associated with any phenotype. In univariate analysis, stenosis was significantly associated with both V249I CX3CR1 polymorphism and 3020InsC NOD2/CARD15 mutations. In smoker patients carrying the CX3CR1 allele I249, there was a significant increase in the frequency of fibrostenosing disease [P=0.005, odds ratio (OR): 3.25] whereas this relationship disappeared in the group of nonsmokers (P=0.72). In multivariate analysis, 3020InsC NOD2/CARD15 mutations and the V249I CX3CR1 polymorphism were independent risk factors for intestinal stenosis (P=0.046, OR: 1.8 and P=0.044, OR: 2.4, respectively). CONCLUSION: In Crohn's disease, V249I CX3CR1 polymorphism is associated with intestinal strictures, particularly in smokers. This association is independent of CARD15 mutations.     

Increased expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in Wegener's granulomatosis--possible role in vascular inflammation

OBJECTIVE: Based on the function of fractalkine (CX3CL1), the unique member of the CX3C chemokine subfamily, in endothelial-related inflammation, we hypothesized a role for CX3CL1 and its receptor (CX3CR) in Wegener's granulomatosis (WG). In the present study, this hypothesis was tested by different experimental approaches. METHODS: We examined plasma levels of CX3CL1 (enzyme immunoassay) and CX3CR1 expression in peripheral blood mononuclear cells (PBMCs) (real-time quantitative RT-PCR and flow cytometry) in 18 WG patients and 15 healthy controls. In eight of these individuals, we also examined CX3CR1-mediated chemotaxis and adhesion in T cells and monocytes as well as the effects of CX3CL1 on monocyte chemoattractant protein (MCP) 1 levels in PBMC supernatants. RESULTS: Our main findings were: (i) WG patients had markedly increased plasma levels of CX3CL1, with particularly high levels in those with active disease, (ii) These increased CX3CL1 levels were accompanied by enhanced expression of its corresponding receptor, CX3XR1, in PBMC, primarily reflecting an increased proportion of CX3CR1(+)CD3(+)CD4(+) T cells and (iii) The up-regulation of CX3CR1 in PBMC from WG patients affected their functional potential as shown by CX3CL1-induced enhancement of chemotaxis, adhesion, responses as well as MCP-1 stimulation. CONCLUSION: Based on the ability of CX3CL1 to promote leucocyte infiltration into the vessel wall of inflammatory levels, it is tempting to hypothesize that increased CX3CL1/CX3CR1 interaction could be involved in the pathogenesis of the granulomatous vasculitis characterizing WG.     

The chemokine receptor CX3CR1 controls homing and anti-viral potencies of CD8 effector-memory T lymphocytes in HIV-infected patients

OBJECTIVES: We have recently reported that the polymorphism of the fractalkine receptor, CX3CR1, provides a new marker for prognosis in HIV disease. In order to understand the mechanism by which CX3CR1 participates in the regulation of HIV-immune responses, we investigated its expression and role on T lymphocytes in HIV-infected patients. DESIGN: For that purpose, we analysed the expression of CX3CR1 on CD4 and CD8 effector-memory subsets in HIV-positive individuals by flow cytometric analyses, and studied its potential role in the migration and function of CD8 effector cells. RESULTS: We observed an increased frequency of CD8 cells expressing CX3CR1 that was correlated with disease progression in HIV-infected patients compared with normal individuals. CX3CR1+ was expressed mainly on activated and differentiated CCR7-CD45RA-negative memory lymphocytes. Interestingly, CX3CR1 appeared as the main homing receptor of these cells that have downmodulated most other chemokine receptors. The CD8+CX3CR1+ lymphocytes were engaged in the cytotoxic lineage (perforin+, CD27-negative and CD57+). Ex-vivo analysis showed that CX3C ligand-1 inhibits IFNgamma production in response to T cell receptor engagement. CONCLUSION: CX3CR1 and its ligand could contribute to the specific migratory pattern of late-stage differentiated CD8 cells and participate in the regulation of effector function of CD8 lymphocytes during HIV infection.     

Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease

Coronary atherosclerosis is a major cause of death in industrialized countries. Monocytes, which play a key role in atherosclerosis, migrate into the vessel wall, presumably guided by specific chemoattractant and adhesion molecules. A compelling candidate for this role is the chemokine receptor CX3CR1, which is expressed on monocytes and acts as either a chemotactic receptor or an adhesion molecule, depending on whether its ligand, fractalkine, is presented free or membrane bound. A common variant of CX3CR1 was recently identified, encoded by the alleles I249 and M280, which form a common I(249)M(280) haplotype. When CX3CR1 genotypes were analyzed in 151 patients with acute coronary syndromes and in 249 healthy controls, CX3CR1 I249 heterozygosity was associated with a markedly reduced risk of acute coronary events, independent of established acquired coronary risk factors (eg, smoking, diabetes). The adjusted odds ratio for this allele was 0.43 (95% confidence interval, 0.26-0.72; P =.001). Consistent with this, functional analysis of peripheral blood mononuclear cells showed that CX3CR1 I249 heterozygosity was associated with a significant decrease in the number of fractalkine binding sites per cell. The results show that CX3CR1 I249 is an independent genetic risk factor for coronary artery disease and that CX3CR1 may be involved in the pathogenesis of atherosclerotic disease. (Blood. 2001;97:1925-1928)     

Exclusive increase of CX3CR1+CD28-CD4+ T cells in inflammatory bowel disease and their recruitment as intraepithelial lymphocytes

BACKGROUND: CX3CL1/Fractalkine (FKN) has been reported to play important roles in various inflammatory diseases. We examined the role of FKN and its receptor CX3CR1 in T-cell migration in the inflammatory bowel diseases (IBDs), ulcerative colitis (UC) and Crohn's disease (CD). METHODS: CX3CR1 expression on peripheral CD4(+) cells from normal controls (NL n = 24) and IBD patients (UC n = 28, CD n = 26) was examined using flow cytometry. CX3CR1(+)CD4(+) T cells were further characterized for surface antigens, cytokine production, and cytotoxic granule release by flow cytometry and ELISA. FKN expression in 53 colonic biopsy specimens (UC n = 20, CD n = 23, NL n = 10) was analyzed by quantitative PCR and immunohistochemistry. Isolated lamina propria and intraepithelial lymphocytes were also analyzed by flow cytometry (UC n = 10, CD n = 10, NL n = 6). RESULTS: CX3CR1(+)CD4(+) cells were increased in IBD while they were virtually absent in controls. Upregulation of CX3CR1 on CD4(+) T cells was positively correlated with disease activity. These unique T cells expressed markers for both effector memory and cytotoxic cells. Interestingly, CX3CR1 was expressed on CD4(+) T cells lacking CD28. CX3CR1(+)CD28(-)CD4(+) cells produced more IFN-gamma and TNF-alpha than CX3CR1(-) counterparts and released cytotoxic granules. FKN mRNA was upregulated in inflamed colonic tissues and robust expression of FKN was immunohistochemically observed on epithelial cells. Although CX3CR1(+) CD4(+) cells could not be detected in the gut, CD28(-)CD4(+) cells were found in IBD mainly as intraepithelial lymphocytes. CONCLUSIONS: FKN/CX3CR1 may contribute to the pathogenesis of IBD through the emergence of unique CX3CR1(+)CD28(-)CD4(+) T cells that can act both as proinflammatory and cytotoxic cells.     

CX3CR1基因多态性与冠心病的相关性

目的 研究Fractalkine受体CX3CR1基因多态性(249V/I和280T/M)与冠心病的相关性.方法 应用聚合酶链反应限制片长多态性方法对139例冠心病患者和90例对照者的CX3CR1基因多态性进行分析,比较CX3CR1基因多态性在两组之间的差异性.结果 等位基因I249在对照组中的分布频率明显高于冠心病组(P<0.05);冠心病组280T/M基因型和等位基因频率分布与对照组比较无显著性差异(P>0.05).结论 Fractalkine受体CX3CR1等位基因I249变异可能与冠心病的发病危险性下降有关,CX3CR1基因多态性与中国南方汉族人群冠心病的发生存在相关性.